George Clemens

George Clemens has over 50 years of work experience in the pharmaceutical and biotechnology sector. George most recently served as the Executive Vice President of Toxicology at Vincerx Pharma starting in December 2020. Prior to that, they held the role of Vice President of Preclinical Studies at Ileo Science from August 2018 to December 2020. From June 2016 to December 2020, they worked as a Preclinical Consultant to the Pharmaceutical and Biotechnology Sector for companies such as Rigel, Coherus, and Achaogen.

George's extensive experience also includes a long tenure at Rigel Pharmaceuticals, Inc. from June 2002 to January 2016, where they held the position of Vice President of Preclinical Drug Safety Evaluation. In this role, they provided oversight for various non-clinical safety programs and was involved in the development of multiple drug programs. Prior to that, they worked as a Preclinical Biotechnology Consultant at Coley Pharmaceutical Group from September 2001 to May 2002.

George's career began at Bayer in December 1979, where they served as the Principal Scientist of Preclinical Drug Safety Evaluation. George managed the toxicology laboratory and was recognized as an international expert in reproduction toxicology. Prior to joining Bayer, they worked as a Senior Staff Scientist at Sterling Winthrop Research Institute from May 1968 to December 1979.

Overall, George Clemens has had a long and impactful career in the pharmaceutical and biotechnology industry, with expertise in toxicology, preclinical studies, and drug safety evaluation.

George Clemens earned a Bachelor of Science (BSc) degree in Biology/Biological Sciences from the College of Santa Fe from 1964 to 1968. George then pursued a Master of Science (M.Sc.) degree in Biology/Biological Sciences from The College of Saint Rose from 1971 to 1973. Lastly, George obtained a PhD in Biology/Biological Sciences from the University of Notre Dame, where they studied from 1984 to 1989.